AUS
NZ
UK
CA
USA
IND
Highlights
- Penumbra launched the FORWARD study evaluating stroke treatment technologies.
- The study includes the recently cleared THUNDERBOLT CAVT System and RED catheter portfolio.
- Clinical research expands evidence supporting minimally invasive neurovascular care.
Penumbra advances stroke treatment research through the FORWARD study while strengthening its neurovascular device portfolio as a constituent of the NYSE Composite.
Penumbra operates in the medical technology sector, developing devices for neurovascular and peripheral vascular conditions through minimally invasive treatment approaches. Penumbra (NYSE:PEN) is a constituent of the NYSE Composite and is widely recognized within the Healthcare Stocks category. The company designs aspiration thrombectomy systems, reperfusion catheters, access devices, embolization products, and computer-assisted rehabilitation technologies serving hospitals and healthcare providers worldwide.
FORWARD study expands clinical research
Penumbra recently initiated the FORWARD study, an international, prospective, real-world clinical trial designed to evaluate the safety and effectiveness of the RED reperfusion catheter portfolio, including the THUNDERBOLT Computer Assisted Vacuum Thrombectomy (CAVT) System, in patients experiencing acute ischemic stroke involving distal M2 occlusions.
The study is expected to enroll up to 250 patients across approximately 40 clinical sites. Researchers will compare mechanical thrombectomy combined with medical management against medical management alone, providing additional clinical evidence for treatment approaches involving distal vessel occlusions.
Clinical studies such as FORWARD contribute to broader understanding of procedural outcomes while supporting ongoing evaluation of advanced neurovascular technologies.
THUNDERBOLT platform broadens treatment portfolio
The THUNDERBOLT CAVT System recently received regulatory clearance, expanding Penumbra's portfolio of aspiration thrombectomy technologies. The system incorporates computer-assisted aspiration designed to support clot removal during minimally invasive vascular procedures.
The RED reperfusion catheter family is engineered to provide physicians with multiple catheter options for treating acute ischemic stroke through aspiration-based techniques. Together, these technologies complement Penumbra's established neurovascular product portfolio used in hospitals and specialized stroke treatment centers.
As a member of the NYSE Composite, the company continues expanding its clinical evidence through studies evaluating new medical technologies across different patient populations.
Focus on neurovascular innovation
Stroke remains one of the leading causes of disability worldwide, creating continued demand for technologies supporting rapid vessel recanalization. Penumbra develops devices intended for mechanical thrombectomy procedures performed by neurointerventional specialists treating acute ischemic stroke.
Beyond stroke care, the company's product portfolio includes devices for peripheral thrombectomy, embolization procedures, access management, and aspiration technologies. These products are used across multiple vascular applications requiring minimally invasive intervention.
Clinical evidence generated through prospective studies supports healthcare providers by expanding available information regarding procedural performance, treatment pathways, and patient outcomes.
Global commercial presence
Penumbra markets its products across North America, Europe, Asia-Pacific, Latin America, and selected international markets. Commercial activities include physician education, product training, clinical support, and collaboration with healthcare institutions.
Manufacturing operations support production of aspiration systems, catheters, guidewires, embolization devices, and related medical technologies used in hospitals and specialized treatment facilities. Research and development activities continue focusing on engineering advancements across neurovascular and peripheral vascular therapies.
The company also develops rehabilitation technologies designed to assist patients recovering from neurological conditions through immersive healthcare solutions.
Medical technology portfolio continues expanding
Product development remains focused on improving aspiration efficiency, catheter performance, procedural workflow, and physician usability across neurovascular interventions. The FORWARD study represents another component of ongoing clinical research supporting these technologies following recent regulatory milestones.
Healthcare systems continue evaluating minimally invasive procedures designed to restore blood flow during acute ischemic stroke, particularly in patients experiencing distal vessel occlusions. Clinical data from prospective international studies may contribute to medical literature regarding treatment approaches within this specialized field.
Penumbra (NYSE:PEN) continues expanding its portfolio of neurovascular technologies through clinical research, regulatory advancements, and product development while maintaining its position within the NYSE Composite and the global medical technology industry.
